The appearance of single clone antibody combines the activity of human GDF15 and suppresses it. Antibodies can be used to treat weight loss, including caquexia, which is associated with overexposure to human GDF15. Requirement 1: an isolated antibody combining human GDF15, including a variable immunoglobulin heavy chain region and a variable immunoglobulin light chain region.1. This group does not include: (a) (I) heavy chain transformation region of immunoglobulin, including a cdrh832121, a selected amino acid sequence composed of SEQ ID No.1 and SEQ ID No.38 (hu01g06 ighv1-18 F2)；a. Cdrh832222, including a series of amino acids (hu01g06 ighv1-18 F2) selected from SEQ ID No. 237 and SEQ ID No. 241, and including SEQ ID No. 15 amino acid sequence (hu01g06 ighv1-18 F2)；Y (II) a light immunoglobulin chain transformation region composed of cdr1832121, including SEQ amino acid sequence 21 (hu01g06 igkv1-39 F2),a. CDRL 832222, including SEQ ID 26 amino acid sequence (hu01g06 igkv1-39 F2) and CDRL 832323, including SEQ ID 244 amino acid sequence (hu01g06 igkv1-39 F2)；(b) (I) a variable region of heavy chain immunoglobulin composed of cdrh832121, including a series of amino acids selected from SEQ ID 1 and SEQ ID 234 (hu01g06 ighv1-69 F1)；a. Cdrh832222, including the amino acid sequence selected from the group, including SEQ ID no.238 and SEQ ID No.241 (hu01g06 egv1-69 F1) and cdrh83232323, including the amino acid sequence of SEQ ID No.15 (hu01g06 egv1-69 F1)；Y (II) a light immunoglobulin chain transformation region composed of cdr1832121, including SEQ amino acid sequence 21 (hu01g06 ighv1-39 F1),a. CDRL 832222, including SEQ ID 26 amino acid sequence (hu01g06 igkv1-39 F1) and CDRL 832323, including SEQ ID 32 amino acid sequence (hu01g06 igkv1-39 F1)；(c) (i) an immunoglobulin heavy chain variable region comprising a CDRH₁ comprising the amino acid sequence of SEQ ID No. 1 (01G06, Ch01G06 chimeric, Hu01G06 IGHV1-18, Hu01G06 IGHV1-69, Sh01G06 IGHV1-18 M69L , Sh01G06 IGHV1-
